Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NO-CUT Trial
2024-515225-28-00Phase 3Authorised
- Sponsor
- ASST Grande Ospedale Metropolitano Niguarda
- Start
- Aug 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of oxaliplatin and capecitabine in rectal cancer, sponsored by ASST Grande Ospedale Metropolitano Niguarda. Primary endpoints: Distant relapse-free survival at 2.5 years, Association between 6-methylated gene panel and relapse-free survival and 2 more. Planned start Aug 2024; status: authorised.
02
Drugs
oxaliplatincapecitabine
03
Conditions
rectal cancer
Beyond the preview
Go deeper on 2024-515225-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515225-28-00.